drugset
drugset / Trial / NCT05371184

Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients

NCT05371184 ↗

Phase 4 Completed 60 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelPrevention

Summary

Prospective phase IV interventional open label randomized controlled trial to assess safety and efficacy of glutamine in preventing vaso-occlusive crisis (VOC) episodes in sickle cell pediatrics and adolescents' patients

Timeline

Start
2022-01-04
Primary completion
2023-01-03
Completion
2024-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Glutamine Other / unclassified 0.3 g/kg Oral

Indications

sickle cell disease